MKS (MKSI) Q2 2026 Earnings Call Transcript

MKS delivered Q2 2026 revenue of $1.25B (+28% YoY) and non-GAAP EPS of $3.30 (+86% YoY), with gross margin at 47.6% (including ~100 bps from tariff/duty refunds) and adjusted EBITDA of $358M (28.6% margin), exceeding the high end of guidance. Management guided Q3 revenue to $1.35B (+$40M at midpoint sensitivity) and expects semiconductor revenue to accelerate to >50% YoY growth, supported by strong NAND deposition/etch and advanced logic demand plus AI-driven chemistry equipment sales. The company is also expanding capacity (doubling Guangzhou equipment capacity; Malaysia ramp for 2027) while maintaining balance-sheet progress via $100M term-loan prepayment, $188M free cash flow (~15% of revenue), and a 3x leverage ratio down one turn.

Analysis

The market is likely underestimating how much of MKSI’s growth is becoming structural rather than purely cyclical: higher AI board complexity lifts chemistry attach rates, while installed-base utilization lifts service and consumables. That shifts the earnings mix toward recurring, higher-quality revenue over 6-18 months, and it also makes the company a relative winner versus semiconductor equipment names that are more dependent on one-off tool placements. The second-order loser is not just PCB supply chain vendors, but any competitor without proprietary chemistry or field service density; they will have less pricing power as customers pay for uptime and process performance rather than box shipments.

Near term, though, the story is not clean margin expansion. Capacity adds in Malaysia/China and the decision to prioritize equipment shipment create a temporary gross margin drag, while the one-time tariff/refund benefit makes the current margin run-rate look a bit better than core economics. That means the next 1-2 quarters are more about proof of order conversion and backlog durability than about immediate margin upside. The key falsifier is any sign that 2027 visibility is slipping, lead times normalize faster than expected, or gross margin fails to stabilize once ramp costs roll off.

The contrarian risk is that investors may be extrapolating the AI packaging cycle too far into 2027 before the supply chain has actually absorbed the new capacity. If AI board demand cools or customer capex pauses, MKSI has a lot of operating leverage on the downside because it is adding working capital ahead of demand. The right frame is not a chase-on-strength name; it is a buy-on-dips compounder if the backlog and service revenue stay firm.

Key Decisions for Investors

• Buy MKSI on a 5-8% post-print pullback; 3-6 month upside is driven by backlog conversion and capacity commentary, while downside should be limited unless guidance rolls over.
• Pair trade: long MKSI / short SOXX for 1-3 months to isolate AI-packaging and service leverage versus the broader semi-equipment beta.
• For event-risk control, consider MKSI call spreads into the next earnings cycle rather than stock outright; the risk/reward is best if management reiterates 2027 visibility and gross margin stabilization.
• Set a falsifier alert on gross margin: if ex-one-time items and ramp costs do not begin to improve over the next 2 quarters, reduce or exit the long.